# The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery

> **NCT02006888** · PHASE3 · COMPLETED · sponsor: **ICON Bioscience Inc** · enrollment: 394 (actual)

## Conditions studied

- Inflammation
- Cataracts

## Interventions

- **DRUG:** IBI-10090
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02006888
- **Lead sponsor:** ICON Bioscience Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 394 (ACTUAL)
- **Last updated:** 2018-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02006888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02006888, "The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02006888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*